ADAR1 Capital Management LLC Acquires Shares of 144,641 Palvella Therapeutics (NASDAQ:PVLA)

ADAR1 Capital Management LLC acquired a new position in Palvella Therapeutics (NASDAQ:PVLA) during the 4th quarter, HoldingsChannel reports. The fund acquired 144,641 shares of the company’s stock, valued at approximately $1,736,000.

Separately, BML Capital Management LLC purchased a new position in Palvella Therapeutics in the 4th quarter valued at $506,000. Institutional investors own 40.11% of the company’s stock.

Palvella Therapeutics Trading Down 1.8 %

Shares of PVLA opened at $23.98 on Monday. The business’s 50 day simple moving average is $21.48. Palvella Therapeutics has a 12-month low of $6.20 and a 12-month high of $29.27. The stock has a market capitalization of $264.24 million, a price-to-earnings ratio of -1.98 and a beta of 0.10.

Analyst Ratings Changes

A number of research firms have recently issued reports on PVLA. Cantor Fitzgerald initiated coverage on Palvella Therapeutics in a research report on Wednesday, December 18th. They issued an “overweight” rating for the company. TD Cowen assumed coverage on Palvella Therapeutics in a research report on Wednesday, February 5th. They issued a “buy” rating and a $44.00 target price on the stock. Scotiabank assumed coverage on Palvella Therapeutics in a research report on Friday, March 7th. They set a “sector outperform” rating and a $50.00 price objective for the company. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $39.00 target price on shares of Palvella Therapeutics in a research report on Wednesday, February 26th. Finally, Stifel Nicolaus initiated coverage on shares of Palvella Therapeutics in a report on Wednesday, March 26th. They issued a “buy” rating and a $45.00 price objective on the stock. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $43.50.

About Palvella Therapeutics

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.